A structure-toxicity study of Aß42 reveals a new anti-parallel aggregation pathway

PLoS One. 2013 Nov 11;8(11):e80262. doi: 10.1371/journal.pone.0080262. eCollection 2013.

Abstract

Amyloid beta (Aβ) peptides produced by APP cleavage are central to the pathology of Alzheimer's disease. Despite widespread interest in this issue, the relationship between the auto-assembly and toxicity of these peptides remains controversial. One intriguing feature stems from their capacity to form anti-parallel ß-sheet oligomeric intermediates that can be converted into a parallel topology to allow the formation of protofibrillar and fibrillar Aβ. Here, we present a novel approach to determining the molecular aspects of Aß assembly that is responsible for its in vivo toxicity. We selected Aß mutants with varying intracellular toxicities. In vitro, only toxic Aß (including wild-type Aß42) formed urea-resistant oligomers. These oligomers were able to assemble into fibrils that are rich in anti-parallel ß-sheet structures. Our results support the existence of a new pathway that depends on the folding capacity of Aß .

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / genetics
  • Alzheimer Disease / metabolism
  • Amyloid beta-Peptides / genetics
  • Amyloid beta-Peptides / metabolism*
  • Animals
  • Circular Dichroism
  • Microscopy, Electron, Transmission
  • PC12 Cells
  • Rats

Substances

  • Amyloid beta-Peptides

Grants and funding

This work was supported by a grant from the PEPS IDEX 2012 « Analyse structure-toxicité du peptide Aß impliqué dans l’apparition de la maladie d’Alzheimer » and by JSPS KAKENHI (No. 24570143) and RIKEN. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.